Know Cancer

or
forgot password

A Correlative Science Study for ECOG E5194


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

A Correlative Science Study for ECOG E5194


OBJECTIVES:

- To validate the prognostic utility of the Oncotype DX Recurrence Score® assay in tissue
samples from patients with ductal breast carcinoma in situ enrolled on clinical trial
ECOG-E5194.

OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile
by Oncotype DX Recurrence Score® assay (a reverse transcriptase-PCR-based assay).

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of ductal breast carcinoma in situ

- Enrolled on clinical trial ECOG-E5194

- Local surgery without radiotherapy

- Treated or not treated with tamoxifen

- Available tissue samples

- Hormone receptor status not specified

PATIENT CHARACTERISTICS:

- Menopausal status not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Ipsilateral local failure (first event of invasive or ductal carcinoma in situ [DCIS] recurrence)

Safety Issue:

No

Principal Investigator

Lawrence J. Solin, MD, FACR

Investigator Role:

Principal Investigator

Investigator Affiliation:

Abramson Cancer Center of the University of Pennsylvania

Authority:

Unspecified

Study ID:

CDR0000671157

NCT ID:

NCT01132560

Start Date:

June 2010

Completion Date:

Related Keywords:

  • Breast Cancer
  • ductal breast carcinoma in situ
  • Breast Neoplasms
  • Carcinoma in Situ
  • Carcinoma, Intraductal, Noninfiltrating
  • Carcinoma, Ductal, Breast

Name

Location